摘要
前列腺癌是全球男性中第二常见的恶性肿瘤,也是男性癌症相关死亡的第二大常见原因。前列腺特异抗原(prostate specific antigen,PSA)筛查的引入导致了前列腺癌的早期诊断,但仍有一部分患者被诊断为或进展为高危、局部晚期或转移性疾病。在这些患者中,雄激素和雄激素受体(androgen receptor,AR)在前列腺癌进展中的重要性已经被认识到。因此,将睾酮水平降低到去势水平一直是晚期前列腺癌治疗的基石。在过去的几十年里,尽管存活率有问题,雄激素剥夺治疗(androgen deprivation therapy,ADT)仍被广泛认为是晚期前列腺癌的标准治疗方案。本文对晚期前列腺癌患者的内分泌治疗现状和进展进行综述。
Prostate cancer is the second most common malignant tumor in men worldwide,and it is also the second most common cause of cancer-related deaths in men.The introduction of prostate specific antigen(PSA) screening has led to the early diagnosis of prostate cancer,but there are still some patients diagnosed with or progressing to high-risk,locally advanced or metastatic disease.In these patients,the importance of androgen and androgen receptor(AR) in the progression of prostate cancer has been recognized.Therefore,reducing testosterone levels to castrate levels has always been the cornerstone of advanced prostate cancer treatment.In the past few decades,androgen deprivation therapy(ADT) is still widely regarded as the standard treatment for advanced prostate cancer despite the problem of survival rates.This article reviews the current status and progress of endocrine therapy for patients with advanced prostate cancer.
作者
牛向南
张雁钢
NIU Xiangnan;ZHANG Yangang(Department of Urology,Bethune Hospital,Shanxi Medical University,Shanxi Taiyuan 030032,China)
出处
《现代肿瘤医学》
CAS
2024年第5期973-977,共5页
Journal of Modern Oncology
关键词
晚期前列腺癌
内分泌治疗
机制
advanced prostate cancer
endocrine therapy
mechanism
